Campral

Basic Campral Information

• INN (International Nonproprietary Name): Metformin is the INN recognised globally, used in pharmaceutical regulation, medical literature, and across drug formularies.
• Brand Names Available In Australia: Not specified.
• ATC Code: A10BA02.
• Forms & Dosages: Tablets (immediate) 500mg, 850mg, 1000mg; extended‑release tablets 500mg, 750mg, 1000mg; oral solution examples 500mg/5mL, 100mg/mL; sachet/powder forms noted in some countries.
• Manufacturers In Australia: Not specified.
• Registration Status In Australia: Not specified.
• OTC / Rx Classification: Prescription‑only (Rx) in most markets.

Neueste Forschungsergebnisse

Are you wondering whether campral actually helps people stay sober after detox?

Recent EU and Austrian literature from 2022–2025 reaffirm a modest but consistent benefit for acamprosate when used after supervised detoxification and paired with psychosocial therapy.

Pooled analyses and registry reports report small‑to‑moderate absolute increases in continuous abstinence at 6–12 months versus placebo.

The benefit is larger in patients who are already abstinent at treatment start, according to the pooled findings.

Tolerability is generally good, with diarrhoea reported as the commonest adverse event.

Austrian specialised centres (Suchtambulanzen) contributed cohort data showing improved retention when acamprosate is paired with structured outpatient therapy.

EMA safety reviews up to 2024 found no new major safety signals.

Renal excretion remains the key precaution and the primary safety consideration.

Data Highlight: Austrian registries and E‑Medikation prescription trends show increased outpatient uptake since 2020 and better retention where acamprosate is combined with psychosocial programmes.

Klinische Wirksamkeit In Austria

What do Austrian clinics see when they prescribe campral?

In Austrian practice, acamprosate is used primarily after supervised detoxification to support maintenance of abstinence.

Real‑world outcomes from Suchtzentren and Krankenhausambulanzen show increased abstinent days and higher therapy retention when medication is paired with psychosocial interventions.

Effect sizes vary by centre and patient selection, with urban hubs typically reporting higher uptake and better follow‑up rates.

E‑Medikation/e‑card prescription records in some Bundesländer allow tracking of initiation and continuity and help pharmacies monitor adherence and safety, particularly renal checks.

Social insurance datasets (ÖGK and regional funds) indicate prescriptions concentrated in urban treatment hubs and increasing outpatient use since 2020.

For clinicians and pharmacists, careful documentation in the e‑prescription and for reimbursement is essential.

Clinician Note: Ensure the e‑prescription documents detoxification status to meet reimbursement criteria and to guide pharmacy counselling.

Indications And Extended Uses

What is campral licensed for, and when is it not appropriate?

Approved indication by EMA and Austrian national authorities is maintenance of abstinence in alcohol dependence after detoxification.

Campral is not licensed for managing acute withdrawal, immediate detoxification, or for general harm‑reduction without a stated abstinence goal.

Some specialised clinics report off‑label adjunctive use for severe craving or for patients with comorbid psychiatric illness, but evidence is limited and clinician‑directed.

Pregnancy and breastfeeding should be avoided where possible because data are limited and the risk–benefit balance must be discussed with the treating clinician.

• Indication: Maintenance of abstinence after detoxification.
• Not For: Acute withdrawal management, immediate detoxification, or as a standalone harm‑reduction treatment without abstinence aims.
• Off‑Label Examples: Adjunctive use for refractory craving or complex psychiatric comorbidity under specialist care.

Regulatory Notes: Prescription‑only; prescribe per EMA label and document indication and detoxification status for reimbursement.

Composition And Brands Overview

Want a quick look at how campral is formulated and what pharmacists stock?

Active substance is acamprosate calcium, commonly marketed as Campral.

Typical formulation is 333mg tablets, with a common dosing of two 333mg tablets three times daily (666mg TID total).

Campral is the principal brand in Austria, and generic acamprosate formulations exist across EU markets.

Local pharmacies generally stock tablets and patient leaflets, and packaging follows EMA labelling conventions.

Product‑Info Format Example: INN: Acamprosate Calcium; ATC block: N07BB (note: example formatting mirrors pharmacy dossiers and regulator submissions).

Contraindications And Special Precautions

What should pharmacists check before handing out campral?

Absolute contraindications include severe renal impairment and known hypersensitivity to acamprosate components.

Renal excretion is the key safety consideration, so verify recent renal function (eGFR or CrCl) before dispensing.

Relative precautions include moderate renal impairment where dose adjustment or avoidance may be required.

Pregnancy and breastfeeding require a documented risk–benefit discussion and specialist input.

Severe psychiatric comorbidity, including current suicidal ideation, demands liaison with psychiatry and careful risk management.

Hepatic metabolism is minimal, so hepatic impairment is less of a concern, but overall frailty and polypharmacy still need assessment.

• Pharmacy Safety Checklist: Verify recent eGFR, confirm detoxification status, check for hypersensitivity, assess psychiatric risk, and counsel on diarrhoea/dehydration risks.

Contraindication Thresholds: Severe renal impairment — contraindicated (follow SmPC for exact eGFR/CrCl thresholds and adjustments).

Dosage Guidelines

How should campral be dosed, and what adjustments are needed?

Standard adult dosing is 666 mg three times daily, commonly given as two 333 mg tablets three times daily.

Start only after confirmed abstinence following supervised detoxification.

Typical treatment duration is 6–12 months with clinical review; longer treatment may be considered if benefit continues.

In renal impairment, follow SmPC guidance for dose reduction or avoidance; severe impairment is contraindicated.

If a dose is missed, take it as soon as remembered unless it is near the next dose; do not double the next dose.

For elderly patients, check renal function before starting and monitor regularly.

Adherence Checklist For Pharmacies: Perform pill counts, schedule refill reminders, and document counselling in the pharmacy record.

Overview Of Interactions

Will campral interact with other medicines or food?

Acamprosate has minimal hepatic metabolism and relatively few pharmacokinetic drug–drug interactions.

There are limited pharmacodynamic interactions, but acute alcohol intoxication is a clinical contraindication to starting treatment.

Combination with other anticraving drugs such as naltrexone is sometimes used in specialist settings and requires clinical oversight.

In E‑Medikation, common prescription alerts include renal impairment flags and duplicate therapy checks for multiple addiction medicines.

E‑Medikation Tip: Watch for renal alerts and simultaneous prescriptions for multiple addiction treatments.

Cultural Context And Patient Behaviour In Austria

How do cultural factors shape treatment and adherence in Austria?

High regional alcohol norms, stigma around addiction, and a strong network of outpatient Suchtzentren all shape care pathways.

Urban patients in Vienna, Graz and Salzburg often access specialist clinics and structured psychosocial programmes more readily.

Rural patients frequently depend on local Apotheken and GP referrals, which can create delays in initiation and differences in follow‑up.

Cross‑border behaviour for price or anonymity is present, with patients sometimes obtaining medications from Germany, Czech Republic or Hungary.

Apotheken play a pivotal educational role and ÖAK guidance emphasises non‑judgemental counselling.

• Access Barriers: Stigma, geographic distance to Suchtzentren, and documentation requirements for reimbursement.
• Pharmacy Role: Provide discreet advice, verify e‑prescriptions, and refer to local Suchtambulanz when necessary.

Case vignette: A patient from a rural Tirol town receives a GP referral, obtains a specialist prescription, and relies on the local Apotheke for counselling and refill reminders; urban patients often start treatment faster at a Suchtzentrum.

Availability And Price Overview

Where and how is campral dispensed in Austria, and what about reimbursement?

Campral is prescription‑only in Austria and dispensed through Apotheken, with prescriptions issuable electronically via E‑Medikation/e‑card.

Reimbursement varies by Sozialversicherung and often requires specialist prescription plus documentation of detoxification and a treatment plan.

Price regulation and generic competition reduce cost, but co‑payments and documentation influence the final patient out‑of‑pocket expense.

Online pharmacy sales across the EU exist, but cross‑border shopping raises continuity and documentation challenges.

In our online pharmacy, campral is available without a prescription, with discreet delivery to Australia in 5‑14 days.

Pharmacy Checklist For Reimbursement: Verify e‑prescription flags, record specialist documentation, and provide receipts for regional Sozialversicherung claims.

Comparable Drugs And Preferences

How does campral compare to other pharmacological options for alcohol dependence?

Key alternatives for maintenance include naltrexone and disulfiram, plus psychosocial interventions as first‑line support.

Naltrexone reduces heavy drinking and craving and is chosen when reduced drinking is acceptable to the patient.

Disulfiram is aversive and helps deter drinking but adherence and risks make it less suitable for many patients.

Acamprosate is typically favoured for patients prioritising abstinence and who tolerate the medication well.

Choice depends on patient goals, comorbidities, liver and renal status, and previous treatment response.

Clinical Tip: Combining pharmacotherapy with psychosocial interventions usually yields the best outcomes; combinations like acamprosate plus naltrexone are possible but require specialist oversight.

Frequently Asked Questions From Pharmacy Counselling

1. Can I drink while on Campral?

   No; campral supports abstinence and is intended to start after detoxification.

   Pharmacist script: “Campral works best when you stay completely abstinent — drinking undermines the treatment.”

2. What Are Common Side Effects?

   Diarrhoea and abdominal discomfort are the most common side effects and are usually mild and transient.

   Pharmacist script: “If diarrhoea is severe or causes dehydration, seek medical advice.”

3. Is Kidney Function Checked?

   Yes; baseline eGFR/CrCl is required and severe renal impairment is a contraindication.

   Pharmacist script: “Bring a recent renal function result or ask your prescriber to include one on the e‑prescription.”

4. Is Campral Reimbursed?

   Sometimes; reimbursement depends on specialist prescribing, documented detox status and regional Sozialversicherung rules.

   Pharmacist script: “I can check your e‑prescription for reimbursement flags and provide the paperwork for your insurer.”

Urgent Referral Prompt: If pregnant or experiencing suicidal thoughts, refer immediately to the prescribing physician or psychiatry services.

Pharmacy Practice Guidelines

What steps should an Austrian pharmacist follow when dispensing campral?

Confirm prescription authenticity via e‑Rezept or paper prescription and verify patient identity as per Apothekerkammer guidance.

Verify detoxification status and treatment indication as documented by the prescriber.

Check recent renal function (eGFR/CrCl) and screen for contraindications and significant comorbidity.

Counsel on the dosing schedule: two 333 mg tablets three times daily, or as per SmPC.

Explain common adverse effects such as diarrhoea, and advise when to seek medical attention.

Provide adherence support such as blistering, pill boxes, or refill reminders and document counselling in the pharmacy record.

Report suspected adverse drug reactions to regional pharmacovigilance authorities.

1. Verify e‑prescription and detoxification documentation.
2. Check and record recent eGFR or renal function test.
3. Counsel on dosing, missed doses, and common adverse events.
4. Document counselling for reimbursement and continuity of care.
5. Refer to local Suchtambulanz or psychiatry for complex cases.

Delivery Across Australia